ICAM1 and glioblastoma: Furthermore, the inverse expression pattern of NG2 and ICAM-1 was confirmed also in an in vivo mice model and two glioblastoma cell lines, suggesting that these results are not specific to a particular cell line or model system and can be considered as therapeutic targets to modulate ICAM-1-mediated immune responses [64].